reports
- Ghada Ben Sedrine
- Nicolas David
ACN ACCENTURE PLC CLASS A
SRT3 SARTORIUS AG PREF
RBI RAIFFEISEN BANK INTERNATIONAL AG
MONC MONCLER SPA
DIM SARTORIUS STEDIM BIOTECH SA
EMSN EMS-CHEMIE HOLDING AG
SIE SIEMENS AG
CPR DAVIDE CAMPARI-MILANO N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- Ghada Ben Sedrine
- Nicolas David
ACN ACCENTURE PLC CLASS A
SRT3 SARTORIUS AG PREF
RBI RAIFFEISEN BANK INTERNATIONAL AG
MONC MONCLER SPA
DIM SARTORIUS STEDIM BIOTECH SA
EMSN EMS-CHEMIE HOLDING AG
SIE SIEMENS AG
CPR DAVIDE CAMPARI-MILANO N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- Martial Descoutures
- Oussema Denguir
Sandoz : Un positionnement unique au cœur des systèmes de santé sous c...
Nous initions Sandoz à Neutre avec un objectif de cours de 57 CHF. Sandoz est aujourd’hui l’un des leaders mondiaux des génériques complexes et biosimilaires, issu de la scission de Novartis en 2023. Dès sa première année pleine d’indépendance, le groupe a démontré la solidité de son modèle avec des ventes supérieures à 10 Md$ en 2024. Dans un environnement macroéconomique et réglementaire contraint, son portefeuille de 1 300 produits génériques et biosimilaires lui confère un profil défensif (g...
- Martial Descoutures
- Oussema Denguir
Sandoz : A unique position at the heart of healthcare systems under pr...
We are initiating coverage of Sandoz with a Neutral rating and a target price of CHF 57. It is now one of the world leaders in complex generics and biosimilars, having been spun off from Novartis in 2023. In its first full year of independence, it has demonstrated the strength of its model, with revenues topping $ 10bn in 2024. In a constrained macroeconomic and regulatory environment, its portfolio of ~1,300 generic and biosimilar products gives it a defensive profile (generics) boosted by mome...
Sandoz launches renewable energy partnership to cover nearly 90% of el...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in SpainWill cover nearly 90% of electricity demand for European operationsConcrete step to support global Sandoz decarbonization efforts and sustainability commitment Basel, August 12, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the signing of a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy, a ...
Sandoz delivers strong H1 2025 results, with accelerated sales growth ...
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, today presents its financial results for the first half of 2025. Growth in this document is shown at constant currencies (CC)[1] unless stated otherwise. FINANCIAL RESULTS H1 2025H1 2024changeUSD mUSD mUSD %CC %CGR %[2] Net sales5,2325,0474%4%6% Generics3,7363,7041%1%2% Biosimilars1,4961,3431...
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just...
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibilitySandoz would acquire Just-Ev...
Sandoz further asserts leadership in biosimilars, breaking ground on n...
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 yearsOngoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchangedMost recent USD 440 million investment in new production plant in Brnik, due to open in 2028, brings total plann...
Sandoz launches first and only interchangeable denosumab biosimilars i...
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in USImproves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolioBuilds on established experience and leadership in oncology and immunology biosimilars...
Sandoz launches Pyzchiva® autoinjector, first commercially available i...
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10] Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation B...
Sandoz reports Q1 2025 net sales in line with company expectations; fu...
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China businessten largest-selling medicines grew by combined 4% and represented 33% of net sales Europe net sales grew by 7%[1]. International declined by 2%[1] an...
Sandoz enters global collaboration license agreement with Henlius to c...
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to develop and manufacture biosimilar, with Sandoz to register and commercialize after expiry of relevant patents across global marketsCombination therapy of ipilimumab and nivolumab used in 95% of eligible patients[2]; ipilimumab highly complementary to...
Shareholders approve all resolutions proposed by Board of Directors at...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0.60 per registered dividend-paying share approved, representing 24% of core net income Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial St...
[Corrected] Sandoz files antitrust litigation against Amgen regarding ...
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for ...
Sandoz files antitrust litigation against Amgen regarding patient acce...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today a...
Sandoz strengthens its balance sheet by issuing new bonds to repay spi...
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidityNew facility replaces initial and unutilized USD 1.25 billion RCF, in place since spin-off in 2023Dual-tranche CHF 400m and single-tranche EUR 500 million bonds issuedProceeds used to fully repay USD 750 million equivalent in USD...
Sandoz reports strong FY 2024 results and Q4 2024 sales
Sandoz reports strong FY 2024 results and Q4 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by 9% in constant currencies (+7% in USD)Strong sales performances in all three regions, driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentumOperating income of USD 307 million, up by 5% in constant currencies (-18% in USD)Core ...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, off...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritisMeeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended...
Francisco Ballester to retire; Peter Stenico appointed President Regio...
Francisco Ballester to retire; Peter Stenico appointed President Region International Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee Basel, February 3, 2025 – Sandoz, the global leader in generic and biosimilar medicines, announced today that Francisco Ballester,...
Sandoz to confirm strategic roadmap and highlight pipeline catalysts a...
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025Ambitious GLP-1 strategy in place, addressing each opportunity with mix of internal capabilities and external partnershipsIndust...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.